Millennium Management
SKYE icon

Millennium Management’s Skye Bioscience SKYE Stock Holding History

Millennium Management’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-42,500
Closed -$167K – 6554
2025
Q3 		$167K Buy
+42,500
New +$161K ﹤0.01% 5593

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management's SKYE Position: Q1 2026 in Review

Millennium Management reduced its Skye Bioscience (SKYE) stake by 32% in Q1 2026, selling an estimated $99.6K and leaving 258,200 shares worth $159K. The position accounts for ﹤0.01% of the portfolio, ranked #5243.

Millennium Management first reported a position in SKYE in Q3 2024 and has held it in 5 quarters since. The position peaked at $1.97M in Q2 2025. 39 funds tracked by Wall St. Rank hold SKYE as of Q1 2026.

  • Millennium Management held 258,200 shares of Skye Bioscience worth $159K as of Q1 2026.
  • Millennium Management sold 122,278 Skye Bioscience shares in Q1 2026, an estimated $99.6K.
  • Skye Bioscience made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #5243 holding.
  • Millennium Management first reported a position in Skye Bioscience in Q3 2024 and has held it in 5 quarters since.
  • Millennium Management's Skye Bioscience position peaked at $1.97M in Q2 2025.
  • 39 funds tracked by Wall St. Rank held Skye Bioscience as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.